Zobrazeno 1 - 10
of 133
pro vyhledávání: '"Alan, Boyd"'
Autor:
Christel McMullan, Ameeta Retzer, Sarah E. Hughes, Olalekan Lee Aiyegbusi, Camilla Bathurst, Alan Boyd, Jamie Coleman, Elin Haf Davies, Alastair K. Denniston, Helen Dunster, Chris Frost, Rosie Harding, Amanda Hunn, Derek Kyte, Rebecca Malpass, Gary McNamara, Sandra Mitchell, Saloni Mittal, Philip N. Newsome, Gary Price, Anna Rowe, Wilma van Reil, Anita Walker, Roger Wilson, Melanie Calvert
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 7, Iss 1, Pp 1-13 (2023)
Abstract Background Electronic patient-reported outcome (ePRO) systems are increasingly used in clinical trials to provide evidence of efficacy and tolerability of treatment from the patient perspective. The aim of this study is twofold: (1) to descr
Externí odkaz:
https://doaj.org/article/1f4183a1c1e54a1a8341cfe7200a5ed5
Autor:
Siri Wiig, Suzanne Rutz, Alan Boyd, Kate Churruca, Sophia Kleefstra, Cecilie Haraldseid-Driftland, Jeffrey Braithwaite, Jane O’Hara, Hester van de Bovenkamp
Publikováno v:
BMC Health Services Research, Vol 20, Iss 1, Pp 1-15 (2020)
Abstract Background In the regulation of healthcare, the subject of patient and family involvement figures increasingly prominently on the agenda. However, the literature on involving patients and families in regulation is still in its infancy. A sys
Externí odkaz:
https://doaj.org/article/430f1d655e0e4afd9df8b12a7fcfc12f
Autor:
Alan Boyd
Publikováno v:
Cell and Gene Therapy Insights. :153-157
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4895f7ef801fba14e0dc041fe09c6048
https://doi.org/10.18609/cgti.2023.023
https://doi.org/10.18609/cgti.2023.023
Autor:
Peter D. Stonier, Honorio Silva, Alan Boyd, Domenico Criscuolo, Felicity J. Gabbay, Kyoko Imamura, Gustavo Kesselring, Sandor Kerpel-Fronius, Heinrich Klech, Ingrid Klingmann
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
The evolution of postgraduate vocational education and training in pharmaceutical medicine is described alongside the growth of this scientific-medical discipline and profession for the development of new medicines. Over the past 50 years, whilst the
Externí odkaz:
https://doaj.org/article/5c5c849ca0f144cbaa29e8d2992f024d
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2020)
Pharmaceutical medicine has evolved to be a distinct medical scientific discipline over time. Pharmaceutical medicine has distinctive features related to complex innovative medicines development activities in an often commercially focused competitive
Externí odkaz:
https://doaj.org/article/20eb0ade01d7406e914d8aca11437e05
Publikováno v:
BMC Health Services Research, Vol 18, Iss 1, Pp 1-10 (2018)
Abstract Background Accelerating the implementation of new technology in healthcare is typically complex and multi-faceted. One strategy is to charge a national agency with the responsibility for facilitating implementation. This study examines the r
Externí odkaz:
https://doaj.org/article/08123f2d470e45df9b4570d5235636aa
Autor:
Abigail Tazzyman, Jane Ferguson, Charlotte Hillier, Alan Boyd, John Tredinnick-Rowe, Julian Archer, Sam Regan de Bere, Kieran Walshe
Publikováno v:
BMC Health Services Research, Vol 17, Iss 1, Pp 1-14 (2017)
Abstract Background Medical revalidation is the process by which all licensed doctors are legally required to demonstrate that they are up to date and fit to practise in order to maintain their licence. Revalidation was introduced in the United Kingd
Externí odkaz:
https://doaj.org/article/0110280a19674c8ea00de6ec5e80ec84
Autor:
Kat Toups, Ann Hathaway, Deborah Gordon, Henrianna Chung, Cyrus Raji, Alan Boyd, Benjamin D. Hill, Sharon Hausman-Cohen, Mouna Attarha, Won Jong Chwa, Michael Jarrett, Dale E. Bredesen
Publikováno v:
Journal of Alzheimer's disease : JAD. 88(4)
Background: Effective therapeutics for Alzheimer’s disease are needed. However, previous clinical trials have pre-determined a single treatment modality, such as a drug candidate or therapeutic procedure, which may be unrelated to the primary drive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df236e16453e6b1f488e7e442056a12b
https://pubmed.ncbi.nlm.nih.gov/35811518
https://pubmed.ncbi.nlm.nih.gov/35811518
Autor:
Alan Boyd, Tracy M. Downs, Brian R. Lane, Michael Woods, Brant A. Inman, Joseph Mashni, Gary D. Steinberg, Kirk A. Keegan, Alexander Sankin, Joseph E. Busby, Stephen A. Boorjian, Robert S. Svatek, Richard Philipson, Paul L. Crispen, Michael A. O’Donnell, Seth P. Lerner, Daniel J. Canter, Colin P.N. Dinney, Vikram M. Narayan, Yair Lotan, Tracey L. Krupski, Michael S. Cookson, Leonard G. Gomella, Ashish M. Kamat, David Sawutz, Lawrence Karsh, Michael B. Williams, F. Peter Treasure, Ruth Coll, Gennady Bratslavsky, Thomas J. Guzzo, Adam Luchey, Mehrdad Alemozaffar, Trinity J. Bivalacqua, Michael A. Poch, Jeffrey S. Montgomery, Badrinath R. Konety, Nigel Parker, Anne Schuckman, Seppo Ylä-Herttuala, Neal D. Shore, Gordon D. Brown, Gerald L. Andriole
Publikováno v:
The Lancet Oncology. 22:107-117
Summary Background BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known as rAd-IFNa/Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon alfa-2b cDN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2886c9be02be1fb7917e6d1dcffd8aad
https://doi.org/10.1016/s1470-2045(20)30540-4
https://doi.org/10.1016/s1470-2045(20)30540-4